Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

ASCO 2026: Latest updates in mRCC

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

ASCO 2026: Breast cancer overview

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Part 4: Clinical decision making - Interpretation of next generation sequencing results

Screen-detectable cancers account for majority of early-onset cancer cases under age 50

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers